Analyst: FDA Won't Pull Permit On Orexigen Therapeutics
March 06, 2015 at 14:56 PM EST
Orexigen Therapeutics, Inc. (NASDAQ: OREX) sole product, the anti-obesity drug Contrave, almost certainly won't get pulled from ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.